Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Transdermal Continuous Oxygen Therapy for Diabetic Foot Ulcers

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Ogenix Corporation
ClinicalTrials.gov Identifier:
NCT01291160
First received: February 4, 2011
Last updated: April 11, 2014
Last verified: April 2014

February 4, 2011
April 11, 2014
October 2009
February 2013   (final data collection date for primary outcome measure)
Number of 100% Wound Closure [ Time Frame: before or at week 12 ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01291160 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Transdermal Continuous Oxygen Therapy for Diabetic Foot Ulcers
A Prospective, Randomized Blinded Multicenter, Parallel Study Comparing Transdermal, Continuous Oxygen Delivery to Moist Wound Therapy (MWT) in the Treatment of Diabetic Foot Ulcers

This is a multicenter, prospective, parallel, double-blinded, validation study of up to 12 weeks duration to evaluate the safety and effectiveness of EPIFLO for the treatment of Diabetic Foot Ulcer. The primary objectives of this study are: 1) to evaluate the effectiveness of EPIFLO in combination with standard wound therapy on wound healing as compared to standard wound therapy alone; and 2) Screening for potential safety issues.

Diabetic subjects with a Diabetic Foot Ulcer present for a minimum of 30 days will be enrolled. All subjects enrolled in the study will receive a standard wound therapy regimen consisting of, wound cleansing, moist wound care, off-loading and as appropriate, aggressive debridement. Subjects will be randomized to either the Treatment arm or the Control arm. Subjects will be assessed weekly for signs of wound healing during the 12-week Treatment Period, once two weeks after wound closure and once at the end of 12-week durability Period.

Not Provided
Interventional
Phase 2
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Diabetic Foot Ulcers
  • Device: Epiflo
    During the Treatment Period, subjects will be administered EPIFLO (either working units or sham units per randomization schedule) in conjunction with standard wound therapy regimen consisting of aggressive debridement, wound cleansing, wound dressing, for a period of 12 weeks, or until the wound completely closes, whichever event occurs first.
    Other Name: Transdermal Continuous Oxygen Therapy
  • Other: Moist Wound Therapy
    During the Treatment Period, subjects will be administered EPIFLO (either working units or sham units per randomization schedule) in conjunction with standard wound therapy regimen consisting of aggressive debridement, wound cleansing, wound dressing, for a period of 12 weeks, or until the wound completely closes, whichever event occurs first.
  • Experimental: Epiflo Treatment
    The cohort will comprise of 2 populations: the Treatment Arm of up to 90 subjects; and the Control Arm of up to 90 subjects, in order to collect 120 invaluable subjects. The Treatment Arm includes subjects with DFU who will receive EPIFLO in addition to standard wound care therapy during the Treatment Period.
    Intervention: Device: Epiflo
  • Sham Comparator: Sham Device
    The cohort will comprise of 2 populations: the Treatment Arm of up to 90 subjects; and the Control Arm of up to 90 subjects, in order to collect 120 invaluable subjects. Control Arm includes subjects with Diabetic Foot Ulcers who will receive sham units of EPIFLO along with standard wound care therapy during the treatment Period.
    Intervention: Other: Moist Wound Therapy
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
130
February 2013
February 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male and female patients 20-90 years of age with type 1 or type 2 diabetes mellitus with non-healing, full-thickness, University of Texas Classification of Diabetic Foot Ulcers Class IA diabetic foot ulcers of at least 4 weeks duration, but not greater than 52 weeks, measuring 1 -10 cm2 in area (Area = length x width) 50% at least from 65+ age group
  • Any diabetic foot ulcer at or below the malleoli
  • Patients with partial amputation up to & including a TMA
  • Subjects; between 20-90 years of age with a diabetic foot ulcer; 50% at least from 65+ age group
  • Subjects must have had the wound open for at least 4 weeks from day one on screening visit.
  • Subjects wound must be ≥1 cm2 in size at screening visit, but not greater than 10 cm2.
  • Subject's ABI should be ≥ 0.7 on the study limb or transcutaneous partial pressure oxygen (TcpO2) >40mmHg; or a toe pressure ≥40mmHg; or a Doppler waveform consistent with adequate flow in the foot(biphasic or triphasic waveforms) at screening
  • No active malignancy except non-melanoma skin cancer
  • Subject and/or caregiver must be willing and able to learn and perform the duties of dressing changes, and demonstrate the ability to do so.
  • If patient has had a history of alcohol or substance abuse within 6 months prior to base line period, should provide proof of treatment.

Exclusion Criteria:

  • Wounds of duration >52 weeks
  • Evidence of gangrene on any part of affected limb;
  • Subjects with active Charcot's foot on the study limb;
  • Subjects scheduled to undergo vascular surgery, angioplasty or thrombolysis;
  • Subjects with infected target ulcers, accompanied by cellulitis, known or suspected osteomyelitis, or other clinical evidence of infection;
  • Index ulcer has exposed tendons, ligaments, muscle, or bone.
  • ulcers present in between toes
  • Target limb is infected at beginning of study
  • Must never have had malignancy on study limb
  • Oral, or IV antibiotic/antimicrobial agents or medications have been used within 2 days (48 hours) of baseline.
  • Patients with steroids >7mg dosage are excluded
  • Subject has received growth factor therapy (e.g., autologous platelet-rich plasma gel, becaplermin, bilayered cell therapy, dermal substitute, extracellular matrix) within two weeks of screening date.
  • Subject may not be pregnant at the time of treatment.
  • Subjects with ulcer that has a total Surface Area of greater than 10 cm2 at Screening Visit as measured by a member of the study staff;
  • Subject is undergoing renal dialysis, has known immune insufficiency, other than Diabetes Mellitus
  • Ulcers which decrease in area by >30% during the screening 1-week run-in period
  • History of peripheral vascular repair within the 30 days of baseline.
  • Subject is currently receiving or has received radiation or chemotherapy within 3 months of randomization.
  • No known "patient-reported" alcohol or substance abuse within three months prior to baseline.
  • Subject currently enrolled or participated within 30 days of baseline in another investigational device, drug or biological trial.
  • Subject allergic to a broad spectrum of primary & secondary dressing materials,including occlusive dressings and the adhesives on such dressings.
  • Subject with Chopart amputation
Both
20 Years to 90 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01291160
EPF-409
Yes
Ogenix Corporation
Ogenix Corporation
Not Provided
Principal Investigator: Vickie R Driver, MSDPM FACFAS Lead Principal Investigator
Ogenix Corporation
April 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP